Azitra, Inc. (AZTR)Stock Price & Financial Statements
AboutAzitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.Show more
- Revenue $0 -100.0%
- EBITDA -$11M +99.9%
- Net Income -$11M -22.2%
- EPS (Diluted) -2.25 -532.2%
- Gross Margin -
- EBITDA Margin -
- Operating Margin -
- Net Margin -
- ROE -0.58% +99.7%
- ROIC -0.76% +100.0%
- Debt/Equity 0.11 +13.9%
- Interest Coverage -1445.45 +99.8%
Key Insights
Based on financial data analysisStrengths
- ✓Trading at only 0.0x book value
Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y-
TTM-100%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-22.17%
EPS CAGR
10Y-
5Y-
3Y-
TTM-98.09%
ROCE
10Y Avg-46359.42%
5Y Avg-46359.42%
3Y Avg-77186.29%
Latest-0.55%
Peer Comparison
Microbiome and Phage Therapeutics| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 ELABPMGC Holdings Inc. | 23.88K | 1.05 | -0.00 | 44.07% | -253.14% | -78.44% | ||
 TOVXTheriva Biologics, Inc. | 252.1K | 0.19 | -0.01 | -388.69% | 0.08 | |||
AZTRAzitra, Inc. | 2.03M | 0.19 | -0.08 | -100% | -0.29% | 0.11 | ||
 EVGNEvogene Ltd. | 7.31M | 0.84 | -0.29 | 50.9% | -52.33% | -15.93% | 0.87 | |
 SYBXSynlogic, Inc. | 7.02M | 0.60 | -0.31 | -99.76% | -2919.88% | -31.25% | ||
 MCRBSeres Therapeutics, Inc. | 80.02M | 9.13 | -0.48 | 15.37% | 12.34% | 6.65 | ||
 PHGEBiomX Inc. | 82.77B | 6.30 | -4.29 | -356.43% | 0.40 | |||
 ARMPArmata Pharmaceuticals, Inc. | 419.83M | 11.61 | -22.19 | 14.24% | -9.28% |
Compare AZTR vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|
| Sales/Revenue | 110K | 284K | 686K | 7.5M | 0 |
| Revenue Growth % | - | 158.18% | 141.55% | 993.29% | -100% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 453.14K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 110K | 284K | 686K | 7.5M | -453.14K |
| Gross Margin % | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | 158.18% | 141.55% | 993.29% | -106.04% |
| Operating Expenses | 9.33M | 9.74M | 8.14M | 10.99B | 10.51M |
| OpEx % of Revenue | 8483.14% | 3428.73% | 1186.09% | 146568.53% | - |
| Selling, General & Admin | 3.95M | 3.64M | 4.49M | 6.27B | 6.13B |
| SG&A % of Revenue | 3592.14% | 1281.57% | 655% | 83590.16% | - |
| Research & Development | 5.38M | 6.1M | 3.64M | 4.72B | 4.84B |
| R&D % of Revenue | 4891% | 2147.16% | 531.08% | 62978.37% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -10.96B |
| Operating Income | -9.22M | -9.45M | -7.45M | -10.99B | -10.97M |
| Operating Margin % | -8383.14% | -3328.73% | -1086.09% | -146468.53% | - |
| Operating Income Growth % | - | -2.52% | 21.19% | -147340.74% | 99.9% |
| EBITDA | -9.14M | -9.05M | -7.02M | -10.98B | -10.51M |
| EBITDA Margin % | -8306.07% | -3185.78% | -1024.05% | -146462.56% | - |
| EBITDA Growth % | - | 0.97% | 22.36% | -156265.79% | 99.9% |
| D&A (Non-Cash Add-back) | 84.77K | 405.98K | 425.55K | 448.24K | 453.14K |
| EBIT | -8.87M | -10.43M | -11.1M | -8.95M | -10.94M |
| Net Interest Income | -58.21K | -247.07K | -166.15K | 110.39K | 62.62K |
| Interest Income | 8.76K | 4.82K | 1.58K | 122.55K | 70.21K |
| Interest Expense | 66.97K | 251.89K | 167.73K | 12.16K | 7.59K |
| Other Income/Expense | 281.78K | -1.23M | -3.82M | 10.98B | 19.61K |
| Pretax Income | -8.94M | -10.68M | -11.27M | -8.96M | -10.95M |
| Pretax Margin % | -8126.98% | -3760.69% | -1642.34% | -119.45% | - |
| Income Tax | 0 | 0 | 17.31K | 9.03K | 8.32K |
| Effective Tax Rate % | 100% | 100% | 100.15% | 100.1% | 100.08% |
| Net Income | -8.94M | -10.68M | -11.28M | -8.97M | -10.96M |
| Net Margin % | -8126.98% | -3760.69% | -1644.87% | -119.57% | - |
| Net Income Growth % | - | -19.47% | -5.65% | 20.53% | -22.17% |
| Net Income (Continuing) | -8.94M | -10.68M | -11.28M | -8.97M | -10.96M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.33 | -3.98 | -4.20 | -0.36 | -2.25 |
| EPS Growth % | - | -19.47% | -5.55% | 91.53% | -532.28% |
| EPS (Basic) | -3.33 | -3.98 | -7.34 | -0.36 | -2.25 |
| Diluted Shares Outstanding | 60.49K | 60.49K | 34.51K | 567.57K | 4.87M |
| Basic Shares Outstanding | 60.49K | 60.49K | 34.51K | 567.57K | 4.87M |
| Dividend Payout Ratio | - | - | - | - | - |
Balance Sheet
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|
| Total Current Assets | 8.49M | 4.14M | 2.54M | 5.23M | 3.02B |
| Cash & Short-Term Investments | 8.04M | 3.49M | 1.8M | 4.55M | 2.07B |
| Cash Only | 8.04M | 3.49M | 1.8M | 4.55M | 2.07B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 334.18K | 266.21K | 223.47K | 101.9K | 141.29K |
| Days Sales Outstanding | 1.11K | 342.13 | 118.9 | 4.96 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 216.89K | 67.86K | 4.11K | 950.29M |
| Total Non-Current Assets | 1.71M | 3.03M | 2.58M | 2.13M | 2.01B |
| Property, Plant & Equipment | 946.68K | 1.96M | 1.58M | 1.21M | 962.08M |
| Fixed Asset Turnover | 0.12x | 0.14x | 0.43x | 6.22x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 97.69K | 219.57K | 210.88K | 246.42K | 316.67M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 668.23K | 848.34K | 789.99K | 678.22K | 727.31M |
| Total Assets | 10.2M | 7.17M | 5.12M | 7.36M | 5.03B |
| Asset Turnover | 0.01x | 0.04x | 0.13x | 1.02x | - |
| Asset Growth % | - | -29.74% | -28.63% | 43.85% | 68190.82% |
| Total Current Liabilities | 1.21M | 2.22M | 1.6M | 1.38M | 1.07B |
| Accounts Payable | 717.8K | 784.69K | 897.27K | 490.25K | 399.36K |
| Days Payables Outstanding | - | - | - | - | 321.67 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 265.89M |
| Deferred Revenue (Current) | 15K | 156K | 0 | 0 | 0 |
| Other Current Liabilities | 43.47K | 27.08K | 145.04K | 32.97K | 801.67M |
| Current Ratio | 7.02x | 1.86x | 1.58x | 3.80x | 2.83x |
| Quick Ratio | 7.02x | 1.86x | 1.58x | 3.80x | 2.83x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 34.76M | 41.21M | 599.14K | 284.65K | 156.19M |
| Long-Term Debt | 992.02K | 6.6M | 0 | 0 | 156.19M |
| Capital Lease Obligations | 0 | 840.9K | 563.69K | 284.27K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 33.77M | 33.76M | 35.45K | 381 | -156.19K |
| Total Liabilities | 35.97M | 43.43M | 2.2M | 1.66M | 1.22B |
| Total Debt | 992.02K | 7.73M | 885.95K | 555.51K | 422.08M |
| Net Debt | -7.05M | 4.24M | -910.04K | -4M | -1.65B |
| Debt / Equity | - | - | 0.30x | 0.10x | 0.11x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -137.70x | -37.53x | -44.42x | -903383.22x | -1445.45x |
| Total Equity | -25.77M | -36.26M | 2.91M | 5.7M | 3.8B |
| Equity Growth % | - | -40.73% | 108.03% | 95.61% | 66608.16% |
| Book Value per Share | -425.93 | -599.41 | 84.40 | 10.04 | 779.97 |
| Total Shareholders' Equity | -25.77M | -36.26M | 2.91M | 5.7M | 3.8B |
| Common Stock | 104 | 104 | 1.21K | 763 | 1.07K |
| Retained Earnings | -26.63M | -37.31M | -48.6M | -57.57M | -68.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|
| Cash from Operations | -8.07M | -8.35M | -7.36M | -10.18M | -11.22M |
| Operating CF Margin % | -7333.96% | -2939.95% | -1073.23% | -135.78% | - |
| Operating CF Growth % | - | -3.5% | 11.82% | -38.32% | -10.22% |
| Net Income | -8.94M | -10.68M | -11.28M | -8.97M | -10.96B |
| Depreciation & Amortization | 84.77K | 405.98K | 425.55K | 448.24K | 453.14M |
| Stock-Based Compensation | 306.06K | 184.47K | 151.5K | 245.05K | 62.74M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -164.86K | 1.43M | 4.1M | -1.47M | 10.43B |
| Working Capital Changes | 646.35K | 310.76K | -753.43K | -441.72K | -797.23K |
| Change in Receivables | 194.17K | 66.67K | 42.73K | 133.15K | -44.72K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 282.98K | 420.75K | -68.68K | -140.53K | -500.32K |
| Cash from Investing | -652.27K | -336.76K | -318.26K | -379.25K | -182.91K |
| Capital Expenditures | -446.14K | -33.1K | -26.54K | -8.57K | -24.21M |
| CapEx % of Revenue | 405.58% | 11.66% | 3.87% | 0.11% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | -206.14K | -303.66K | -291.71K | -370.68K | 24.03M |
| Cash from Financing | 992.86K | 4.13M | 5.98M | 13.32M | 8.92M |
| Debt Issued (Net) | 984.39K | 4.35M | -7.39K | -14.6K | -112.64K |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 8.47K | -215.38K | 0 | -18.38K | 0 |
| Net Change in Cash | -7.73M | -4.55M | -1.7M | 2.76M | -2.49M |
| Free Cash Flow | -8.72M | -8.69M | -7.68M | -10.56M | -11.25B |
| FCF Margin % | -7926.94% | -3060.03% | -1119.63% | -140.84% | - |
| FCF Growth % | - | 0.33% | 11.62% | -37.53% | -106388.24% |
| FCF per Share | -144.14 | -143.66 | -222.53 | -18.61 | -2308.04 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.78x | 0.65x | 1.14x | 1.02x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -387.34% | -208.27% | -0.58% |
| Return on Invested Capital (ROIC) | - | - | -278.96% | -445079.83% | -0.76% |
| Gross Margin | 100% | 100% | 100% | 100% | - |
| Net Margin | -8126.98% | -3760.69% | -1644.87% | -119.57% | - |
| Debt / Equity | - | - | 0.30x | 0.10x | 0.11x |
| Interest Coverage | -137.70x | -37.53x | -44.42x | -903383.22x | -1445.45x |
| FCF Conversion | 0.90x | 0.78x | 0.65x | 1.14x | 1.02x |
| Revenue Growth | - | 158.18% | 141.55% | 993.29% | -100% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics